Pediatric PET/MR Image Registry
Part of paid clinical trials in Palo Alto, California.
- Sponsor
- Stanford University
- Study ID
- NCT03458520
- Status
- Recruiting
Conditions
- Lymphoma
- Osteosarcoma
- Soft Tissue
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - 40 Years
- Healthy Volunteers
- Not accepted
Interventions
- PET/MR imaging — DIAGNOSTIC_TESTundergo PET/MR imaging
- MR imaging — DIAGNOSTIC_TESTUndergo MR imaging
- PET/CT imaging — DIAGNOSTIC_TESTUndergo PET/CT imaging
Study Details
The purpose of this study is to compare whole body magnetic resonance (MR) imaging, whole body positron emission tomography (PET)/MR imaging, and (if available) PET/Computed Tomography (CT) imaging for the diagnosis of tumors in children and young adults. Sensitivities, specificities and diagnostic accuracies of the different imaging modalities will be compared for significant differences.
Key Dates
- Start date
- Feb 1, 2018
- Status verified
- Feb 2026
- Primary completion
- Dec 31, 2026
- Completion
- Dec 31, 2026
Study Design
- Enrollment
- 100 participants (estimated)
Arms
- Arm: Image Registrypatients with proven solid tumors or newly diagnosed mass strongly suspected to represent a solid tumor will receive MR imaging, PET/MR imaging (and if available, PET/CT imaging)
Primary Outcome Measure
Number of tumors [ Time Frame: up to 12 months ]
Central Contacts
- Anne Muehe650-720-8601
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Stanford University, School of Medicine | Palo Alto | California | 94304 | Heike Daldrup-Link, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Palo Alto, CA
By research site
Related Studies
- Bone Marrow Grafting for Leukemia and LymphomaEnrolling By Invitation · Stanford University · Stanford, California
- Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer TreatmentRecruiting · Children's Oncology Group · Birmingham, Alabama
- Losartan + Sunitinib in Treatment of OsteosarcomaPHASE1 · Recruiting · University of Colorado, Denver · Los Angeles, California
- A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 AlterationsPHASE1/PHASE2 · Recruiting · Turning Point Therapeutics, Inc. · Los Angeles, California